GlassScriptPhysician profile
Riyaj A Kasekar
NPI 1356504161
$12,733.52
in general payments reported to CMS, 2019-2025
30 companies · $2,569 in 2025
The $2,569 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $926 · 2020: $807 · 2021: $1,400 · 2022: $1,676 · 2023: $2,618 · 2024: $2,738 · 2025: $2,569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,767 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,766.87 |
| Education | $158.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,583.64 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $1,358.72 | 2019-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $1,336.08 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $1,122.22 | 2019-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $1,111.01 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,110.75 | 2021-2025 | |
| Amgen INC. | $984.60 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Otsuka America Pharmaceutical, INC. | $900.05 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $572.01 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $457.21 | 2021-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $302.41 | 2022-2025 | |
| Novo Nordisk INC | $292.66 | 2024-2025 | Ozempic |
| Fresenius USA Marketing, INC. | $290.01 | 2019-2025 | Velphoro |
| Ani Pharmaceuticals, INC. | $228.25 | 2023-2025 | Purified Cortrophin Gel |
| Ardelyx, INC. | $206.08 | 2024-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $141.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.77 | 2023-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $118.21 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $103.82 | 2022-2025 | Acthar |
| Nxstage Medical, INC. | $78.39 | 2023 | Nxstage System One, Liberty Select Cycler |
| Glaxosmithkline, LLC. | $74.68 | 2023-2024 | Benlysta, Jesduvroq |
| Lilly USA, LLC | $54.96 | 2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $39.38 | 2025 | Empaveli |
| Scpharmaceuticals INC. | $36.47 | 2024 | |
| Aurinia Pharma U.S., INC. | $21.09 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.27 | 2021 | |
| Amag Pharmaceuticals, INC. | $17.88 | 2021 | |
| Genzyme Corporation | $15.77 | 2019 | |
| Medtronic, INC. | $15.56 | 2022 | |
| Kyowa Kirin, INC. | $14.25 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Riyaj Kasekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.